TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: BAG-RECALL Study: BIS or Anesthesia Gas to Reduce Explicit Recall
Brief Summary: The overall purpose of this study is to see if a Bispectral Index (BIS) monitor, a Food and Drug Administration (FDA) approved brain monitoring device, will help to reduce the risk of patients remembering being awake during surgery. The BIS monitor may be able to measure how asleep a patient is during surgery. Using the BIS monitor to guide anesthesia will be compared with using the concentration of anesthetic gas to guide anesthesia.


Options:
A: Inclusion:

* Patients 60 years old and older,
* Competent to provide informed consent
* Undergoing major elective surgery that requires a minimum stay of 2 days postoperatively (e.g., open cardiac surgery, open thoracic surgery, major vascular surgery, intra-abdominal surgery, open gynecologic surgery, open urologic surgery, major orthopedic surgery, open hepato-biliary surgery and major ear, nose and throat surgery)

Exclusions

* Neurosurgical procedures will be excluded as surgery on the brain can confound the outcome (postoperative delirium).
* Patients with preoperative delirium and patients who are unable to participate adequately in delirium screening including those who are blind, deaf, or illiterate or fluent in languages other than English.
B: Inclusion Criteria:

* patients scheduled for cardiac surgery

Exclusion Criteria:

* pregnancy
C: Inclusion Criteria:

MUST HAVE:

General Anesthesia with volatile anesthetic

PATIENT CHARACTERISTICS

Major Criteria (Must have any 1 of the following:)

1. Planned open heart surgery
2. Medications - anticonvulsants, abuse of opiates, benzodiazepines, cocaine
3. EF\<40%
4. Prior history of awareness (recall)
5. History of difficult intubation or anticipated difficult intubation
6. ASA IV or V status
7. Aortic stenosis
8. End stage lung disease
9. Marginal exercise tolerance not secondary to musculoskeletal dysfunction
10. Pulmonary hypertension
11. Daily alcohol consumption

Exclusion Criteria:

1. Surgical procedure that prevents the use of the BIS (e.g. surgery of forehead)
2. Patient positioning prevents use of the BIS
3. Surgery with wake-up test.
4. Less than 18 years of age
5. Vulnerable populations, such as those with dementia and those unable to provide informed consent.
6. Stroke with residual neurological deficits

   -
D: Inclusion Criteria:

* Adult patients (\>65 years old)
* Scheduled for elective surgery requiring general anesthesia at LLUMC HSH
* Airway management expected to include endotracheal intubation
* Expected surgical duration 120 to 240 minutes

Exclusion Criteria:

* Pre-existing significant psychiatric disease or mental status changes
* Clinically significant cardiovascular, respiratory, hepatic, renal,neurological, psychiatric, or metabolic disease
* Patient's weighing \>50% ideal body weight

  * Men: Ideal Body Weight (in kilograms) = 50 + 2.3 kg per inch over 5 feet
  * Women: Ideal Body Weight (in kilograms) = 45.5 + 2.3kg per inch over 5 feet
* Patients who have undergone a general anesthetic within the past 7 days
* Patient refusal

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Combination Metformin and Oral Contraception for Polycystic Ovary Syndrome (PCOS)
Brief Summary: The purpose of this research study is to determine if adding Metformin, a drug that reduces insulin resistance, to birth control pills will reduce the risk of developing type 2 diabetes, high blood pressure. high lipid levels and heart disease in women with PCOS


Options:
A: Inclusion Criteria:

* Ages 18-45, , 8 menstrual cycles annually, elevated serum free testosterone, normal thyroid function test and serum prolactin, exclusion of late onset adrenal hyperplasia

Exclusion Criteria:

* Diabetes mellitus, pulmonary, cardiac, renal, hepatic, cholestatic, neurologic, psychiatric, infectious, malignant diseases,history of breast cancer, history of Deep Vein Thrombosis, pregnancy and lactation.
B: Inclusion Criteria:

* Spontaneous intermenstrual periods of greater than or equal to 45 days or a total of 8 or less periods per year
* Elevated testosterone levels
* General good health
* Off of current medications which may confound response to study medications

Exclusion Criteria:

* Pregnancy
* Lactose Intolerance
* Medical Contraindications
* Elevated Prolactin, 17hydroxyprogesterone, or Follicle stimulating hormone blood tests
* Diabetes, liver, heart, kidney or uncorrected thyroid disease
C: Inclusion Criteria:

* PCOS

Exclusion Criteria:

* diabetes
* pregnancy
* contraindications to oral contraceptives
D: Inclusion Criteria:

* Irregular menses or anovulaty cycles
* High free testosterone \> 0.035 nmol/l or hirsutism
* PCO in vaginal US Criteria 1 and 2 OR 2 and 3

Exclusion Criteria:

* Age \> 18 years
* Postmenopausal
* Diagnosis diabetes mellitus
* Use of medicine known to affect hormones measured in the project
* Pregnancy or planned pregnancy during study period
* Non-Caucasian
* Previous tromboembolic disease
* Heavy smoker \> 35 years and BMI \> 35 kg/m2

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Harnessing Health IT for Self-Management Support and Medication Activation in a Medicaid Health Plan
Brief Summary: To measure the effects of a Medical health plan-directed automated telephone self-management support system (ATSM) on patient outcomes among ethnically diverse health plan enrollees with diabetes.


Options:
A: Inclusion Criteria:

* age 18 years or older
* hospitalized for heart failure within the past 30 days
* access to telephone line

Exclusion Criteria:

* not expected to survive 6 months due to irreversible, life-threatening condition
* has or scheduled for cardiac transplant or LVAD
* scheduled for CABG or PCI within 90 days
* severe valvular disease
* Folstein MMSE score less than 20
* resident of a nursing home
* currently a prisoner
* does not speak English or Spanish
B: Inclusion Criteria:

* Participation in a microcredit borrower group sponsored by Partners for Development in Bauchi, Dass, or Ganjuwa Local Government Authority in Bauchi State, Nigeria
* Female (15-45 years)
* Pregnant at baseline

Exclusion Criteria:

* Female (\<15 years)
* Not pregnant
C: Inclusion Criteria:

* DSM-IV criteria for alcohol abuse or dependence
* Age 18 or older
* English speaking
* Smoking 1 or more cigarettes/day
* Male or female veterans eligible for VA healthcare
* Female nonveterans also eligible

Exclusion Criteria:

* Allergy or hypersensitivity to nicotine or adhesives used in nicotine patch
* Weigh less than 100 lbs
* Lack of interest in stopping smoking
* Pregnant or lactating females or females not practicing acceptable form of contraception
D: Inclusion Criteria:

* Diabetes diagnosis
* Attend one of 4 CHNSF clinics
* Ages 18 or above
* Speak English, Spanish or Cantonese
* Have a touch tone phone
* Have had one or more clinic visits in the preceding 24 months
* Will be in the SF Bay Area for the following six months

Exclusion Criteria:

* Pregnant
* Unable to provide verbal consent
* Leaving the region in the next 12 months

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: The Significance of Low-Dose Aspirin on Ovarian Responsiveness, Uterine Hemodynamics and Pregnancy Outcome in in Vitro Fertilization and in Intracytoplasmic Sperm Injection: A Randomized, Placebo-Controlled Double-Blind Study
Brief Summary: In this study we hypothesized that low-dose aspirin therapy (100 mg daily) improves ovarian responsiveness, uterine haemodynamics and clinical pregnancy rates in unselected subjects undergoing IVF/ICSI when the treatment is started concomitantly with controlled ovarian hyperstimulation.


Options:
A: Inclusion Criteria:

* Nulliparous women.
* Ability to speak and .read English
* Singleton pregnancy at \<14 weeks.
* Willing to sign voluntarily a statement of informed consent to participate in the study.

Exclusion Criteria:

* Presence of fetal anomaly at the time of the first trimester scan
* Women with known major risk factors for pre-eclampsia who should already be on Aspirin as per National Institute of Clinical Excellence (NICE) guidance; specifically chronic hypertension, underlying connective tissue, renal or vascular disorder, type 1 diabetes mellitus.
* Under 18 years of age.
* Currently enrolled in other clinical trials.
* Contraindications to Aspirin therapy.
B: Inclusion Criteria:

1. Gestational age between 12+ and 20 weeks of pregnancy
2. High risk of preeclampsia, based in clinical risk factors as:

   2.1 if they have one or more of the following risk factors： Preeclampsia in a previous pregnancy ,Diabetes Mellitus(Type 1 or 2),Chronic Hypertension .

   2.2 if they have two or more of the following risk factors: Pre-pregnancy Body Mass Index ≥28kg/m2, Elderly pregnancy(age ≥35 years), Mother or sisters with preeclampsia in a previous pregnancy, Primiparity or Famliy history (Mother or sister that developed preeclampsia in a previous pregnancy）.
3. Signed informed consent.

Exclusion Criteria:

1. Allergy to aspirin
2. Asthma
3. Peptic ulcers
4. Severe heart, liver, renal disease who can not burden the experiment
5. Rheumatic immune disease
6. Mental disease
7. Alcohol and drug abuse
8. Being in another drug experiment within 3 months
9. Difficult to follow-up
C: Inclusion Criteria:

* The pregnant women
* 28-30 weeks
* Idiopathic asymmetrically intrauterine growth restriction
* Middle aged women (20-35 years)
* Women with abnormal umbilical artery Doppler flow indices ( \> +2 standard deviation above mean for gestational age)

Exclusion Criteria:

* Women less than 20 and more than 35 years
* hypertensive or diabetic women
* any type of smoking
* multiple pregnancies
* amniotic fluid index \<5 cm
* premature pre-labor rupture of membranes
* abnormal placenta
* any fetal congenital malformations.
* women had absent diastolic flow or reversed flow in umbilical artery at the time of recruitment.
D: Inclusion Criteria:

* age \< 40 years
* \< 4 previous ovarian stimulations

Exclusion Criteria:

* allergy for acetylsalicylic acid

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Laparoscopic Hysterectomy: a Clinical Randomized Trial Comparing Conventional and Robot-assisted(Da Vinci®)Techniques
Brief Summary: The aim of this study is to compare conventional with robot-assisted (Da Vinci®) laparoscopic hysterectomy regarding operating time peri-operative outcome and costs.


Options:
A: Inclusion Criteria:

* Indication for laparoscopic hysterectomy
* Patients BMI \< 40
* Signed consent

Exclusion Criteria:

* Estimated uterus weight \>400 g
* No combination with other procedures
* No underlying malignant condition
B: Inclusion Criteria:

* Undergoing Hysterectomy
* Able to consent to the procedure

Exclusion Criteria:

1. Medical conditions not allowing for pneumoperitoneum
2. Medical conditions not allowing proper ventilation during anesthesia
3. Pelvic organ prolapse amendable to a vaginal approach
4. Pregnant women
5. Patients undergoing planned combined procedures including bowel resection (other than coincidental appendectomy) or major urologic procedures.
C: Inclusion Criteria:

* Patients receive laparoscopic-assisted vaginal hysterectomy (LAVH)
* American Society of Anesthesiologists (ASA) physical status of patient: classification I-II

Exclusion Criteria:

* The procedure will be required to conversion to laparotomy.
* Cancer
D: Inclusion Criteria:

* Over 18 years of age
* Scheduled to total hysterectomy and/or bilateral salpingo-oophorectomy (BSOE).
* Both malignant or benign indications
* The operation should be technically possible to perform with laparoscopy or by abdominal incision, including approval from an anesthesiologist
* Acceptance to participate in the study and signed written informed consent document
* Proficiency in Swedish language

Exclusion Criteria:

* The operation is anticipated to comprise more than the hysterectomy + BSOE
* Diabetes mellitus
* Severe chronic pain or massive pain medication
* Severe inflammatory disease like active severe endometriosis or inflammatory bowel disease
* Known severe adhesions in the abdomen
* Contraindications on non steroidal analgesia
* Medication with drugs or disease affecting insulin resistance for example cortisone
* Mentally disabled women who cannot fill in the questionnaires or understand the consequences of participating in a trial
* Severe psychiatric disease or on medication for psychiatric disease so that the physician consider participation in the trial inappropriate

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Laparoscopic Hysterectomy: a Clinical Randomized Trial Comparing Conventional and Robot-assisted(Da Vinci®)Techniques
Brief Summary: The aim of this study is to compare conventional with robot-assisted (Da Vinci®) laparoscopic hysterectomy regarding operating time peri-operative outcome and costs.


Options:
A: Inclusion Criteria:

* Over 18 years of age
* Scheduled to total hysterectomy and/or bilateral salpingo-oophorectomy (BSOE).
* Both malignant or benign indications
* The operation should be technically possible to perform with laparoscopy or by abdominal incision, including approval from an anesthesiologist
* Acceptance to participate in the study and signed written informed consent document
* Proficiency in Swedish language

Exclusion Criteria:

* The operation is anticipated to comprise more than the hysterectomy + BSOE
* Diabetes mellitus
* Severe chronic pain or massive pain medication
* Severe inflammatory disease like active severe endometriosis or inflammatory bowel disease
* Known severe adhesions in the abdomen
* Contraindications on non steroidal analgesia
* Medication with drugs or disease affecting insulin resistance for example cortisone
* Mentally disabled women who cannot fill in the questionnaires or understand the consequences of participating in a trial
* Severe psychiatric disease or on medication for psychiatric disease so that the physician consider participation in the trial inappropriate
B: Inclusion Criteria:

* Women of 18 years or older referred to our service with histologically confirmed primary squamous, adenocarcinoma or adenosquamous cervical cancer diagnosed by biopsy or cervical conization, clinically FIGO (International Federation of Gynecologic and Obstetrics) staged IA2 with lymph vascular invasion, IB and II A.

Exclusion Criteria:

* Patients with clinically advanced disease (IIB-IV), previous pelvic or abdominal radiotherapy, pregnancy, clinical diseases that would preclude one or both surgical approaches.
C: Inclusion Criteria:

* Indication for laparoscopic hysterectomy
* Patients BMI \< 40
* Signed consent

Exclusion Criteria:

* Estimated uterus weight \>400 g
* No combination with other procedures
* No underlying malignant condition
D: Inclusion Criteria:

* Diagnosis of endometrial cancer confirmed by histopathological analysis (endometrial biopsy) requiring surgical staging according to FIGO (the International Federation of Gynecology and Obstetrics) recommendations
* Diagnosis of ovarian cancer confirmed by histopathological analysis after an initial cystectomy or oophorectomy without suspicion of neoplasia thus requiring additional surgical staging according to FIGO recommendations

Exclusion Criteria:

* Diagnosis of advanced endometrial cancer based on findings on imaging techniques (CT, MRI and/or PET)
* Diagnosis of advanced endometrial or ovarian cancer based on intraoperative findings (e.g. peritoneal carcinomatosis at initial laparoscopy)
* Patients who underwent previous aortic lymphadenectomy
* Patients who received previous pelvic and/or aortic radiotherapy

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Tobacco Cessation Via Public Health Dental Clinics (PHD2)
Brief Summary: The study will examine the effectiveness of public health dental practitioners using a brief office based intervention designed to help patients quit smoking or smokeless tobacco use, as compared to usual care.


Options:
A: Inclusion Criteria:

* Subjects must have smoked an average of at least 10 cigarettes per day during the past year and over the month prior to the screening visit, with no period of abstinence greater than 3 months in the past year.

Exclusion Criteria:

* Subjects who have used bupropion (Zyban or Wellbutrin) previously.
B: Inclusion Criteria:

* Patients of participating public health dental clinics
* Tobacco users

Exclusion Criteria:

* Emergency patients
C: Inclusion Criteria:

* At least 18 years old
* Able to get to research lab in Burlington, Vermont or Omaha, Nebraska
* Daily smoker
* Smoke at least 8 cigarettes per day
* No reduction in smoking in last 30 days
* No intention to quit in the next 30 days
* Never used Varenicline before
* Not currently using smoking cessation medications or nicotine replacement therapy
* Willing to use Varenicline for at least 2 weeks
* Fluent in English

Exclusion Criteria:

* Cannot be currently pregnant or breastfeeding
* Kidney disease
* Frequent nausea
* On certain medications for asthma and/or depression
* Another household member in study
D: Inclusion Criteria:

* Subjects will be current cigarette smokers who have smoked an average of at least 10 cigarettes per day during the past year and during the month prior to the screening visit.
* mild to moderate COPD confirmed by spirometry
* Subjects must have a clinical diagnosis of COPD.

Exclusion Criteria:

* Subjects who have made a serious attempt to quit smoking in the past 3 months.
* Subjects who have been previously randomized in a study that has included varenicline.

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Comparison of Sine Waveform High Frequency Chest Wall Oscillation Using Different Settings in Cystic Fibrosis
Brief Summary: Our primary hypothesis is that airway clearance therapy with sine waveform HFCWO using higher inflation pressures combined with both low and high oscillator frequencies will result in greater sputum production compared to sine waveform HFCWO with lower inflation pressures and mid-frequency oscillations.


Options:
A: Inclusion Criteria:

1. Diagnosis of CF established by sweat chloride \> 60 mmol/L.
2. Age older than 18 years.
3. History of chronic daily sputum production.
4. Currently on a home therapeutic regimen that includes some form of airway clearance performed with a HFCWO device at least once daily that also includes concomitant use of an inhaled mucolytic and inhaled bronchodilator.
5. FVC and FEV1 \> 40%-predicted, and with stable lung function (no greater than a 10% variation in lung function parameters over the preceding 3 months).
6. Evaluated at the University of Minnesota CF Center 3 or more times in the preceding 12 months.

Exclusion criteria:

1. Hospitalization for CF pulmonary complications in the 2 months preceding enrollment.
2. Hemoptysis \> 60 cc in a single episode in the 4 weeks preceding enrollment.
3. Chest pain requiring use of narcotic for pain control.
4. Current participation in another clinical trial.
5. Use of intravenous antibiotics for CF respiratory complications in the 2 months preceding enrollment.
6. No prior experience using HFCWO devices for airway clearance
B: Inclusion Criteria:

* Patients with moderate and severe bronchiectasis aged 18-75 will be recruited. Severity will be assessed radiologically by HRCT of the chest using the scoring method by Bhalla et al.

Exclusion Criteria:

* cystic fibrosis
* emphysema on HRCT chest and FEV1\<60% predicted
* active allergic bronchopulmonary aspergillosis or tuberculosis
* poorly controlled asthma
* pregnancy or breast feeding
* current smokers
C: Inclusion Criteria:

* Moderate and Severe Bronchiectasis
* No regular chest physiotherapy

Exclusion Criteria:

* Moderate or Severe COPD
D: Inclusion Criteria:

* Non cystic fibrosis bronchiectasis
* Have FEV1 50% - 80% predicted and ≥1.0L
* Have chronic sputum production of \>10 mL per day on the majority of days in the 3 months prior to study entry

Exclusion Criteria:

* Be using hypertonic saline or mucolytic pharmacological agents concurrently or in the 4 weeks prior to study entry
* Have airway hyperresponsiveness as defined by a positive Aridol challenge

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: SWITCH: Rationale, Design, and Implementation of a Community, School, and Family-based Intervention to Modify Behaviors Related to Childhood Obesity
Brief Summary: The purpose of this research is to increase community awareness about the relationship between physical activity, screen time, and nutrition and how these factors influence healthy weight management.

The problem of obesity is at epidemic proportions and has become the most important public health problem confronting the United States today. Of greatest concern is the 300% increase in obesity rates among children and youth over the past twenty years. Childhood obesity is a precursor of adult obesity.


Options:
A: Inclusion Criteria:

* All children in 3-5 grades who provide parental consent and child assent will be eligible to participate in the project.

Exclusion Criteria:

* Participants who meet the following exclusion criteria will not be considered for participation.
* Do not provide consent
* unable or unwilling to adhere to project procedures
B: Inclusion Criteria:

* School class

Exclusion Criteria:

* Condition precluding exercise
C: Inclusion Criteria:

grade of 1 to 5 in primary schools and grade of 6 to 8 and 10 to 11 in secondary schools.

Exclusion Criteria:

Suffering or any history of disabilities, cardiovascular diseases, asthma, metabolic diseases, etc.
D: Inclusion Criteria:

* All six full-time schools with the program called Programa Saúde na Escola in Fortaleza were eligible
* students of both sexes
* students aged 12-15 years
* students who are enrolled in 7-9 grade classes

Exclusion Criteria:

* students who are younger than 12 years-old and older than 15 years-old
* students with uncompleted data at baseline or 4-months follow-up
* students who are absence in the school days with data collection
* students who dropout the school
* students who refused to participate in data collection or intervention

Answer: A